{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:14:06Z","timestamp":1794100446728,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemokines are vital in post-cerebral ischemia inflammatory reactions. We investigate the possible relationship between plasma chemokines and short-term and long-term outcomes after stroke. This study included 235 patients (median age, 72\u00a0years; 49.8% female) suffering from ischemic stroke, or transient ischemic attack admitted to the hospital within 24\u00a0h of onset. We evaluated chemokines CCL2, CCL5, CXCL8, CXCL9, and CXCL10 in plasma samples collected upon admission. Further, we assessed functional outcomes at 3- and 12-months, all-cause fatality over 5\u00a0years, and episodes of delirium within the first 7\u00a0days of admission. Multivariate analysis revealed an association between higher CXCL10 levels and an increased risk of poor functional outcomes at 3\u00a0months (OR: 3.02, 95%CI: 1.22\u20137.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.016) and 12\u00a0months (OR: 2.32, 95%CI: 1.03\u20135.26, <jats:italic>p<\/jats:italic>\u2009=\u20090.043), as well as an increased death risk (HR: 1.79, 95%CI: 1.04\u20133.07, <jats:italic>p<\/jats:italic>\u2009=\u20090.036). High CXCL8 levels independently predicted poor functional outcomes at 12\u00a0months (OR: 2.69, 95%CI: 1.39\u20136.31, <jats:italic>p<\/jats:italic>\u2009=\u20090.005) and a higher 5-year case fatality rate (HR: 1.90, 95%CI: 1.23\u20132.93, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). Elevated CXCL9 levels also predicted unfavourable functional outcomes at 12\u00a0months (OR: 2.45, 95%CI: 1.07\u20135.61, <jats:italic>p<\/jats:italic>\u2009=\u20090.034). In univariate analysis, increased levels of CXCL8, CXCL9, and CXCL10 showed an association with delirium, although this link was not evident in the multivariate analysis. Plasma CXCL8 and CXCL10 show potential as prognostic biomarkers for stroke outcomes and as therapeutic targets suitable for reverse translation.<\/jats:p>","DOI":"10.1007\/s12035-024-04279-1","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T07:01:51Z","timestamp":1718089311000},"page":"421-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Circulating Chemokines and Short- and Long-Term Outcomes After Ischemic Stroke"],"prefix":"10.1007","volume":"62","author":[{"given":"Elzbieta","family":"Klimiec-Moskal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Koceniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazimierz","family":"Weglarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Slowik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Siedlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Dziedzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"4279_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/nejm199802123380706","volume":"338","author":"FH Epstein","year":"1998","unstructured":"Epstein FH, Luster AD (1998) Chemokines \u2014 chemotactic cytokines that mediate inflammation. N Engl J Med 338:436\u2013445. https:\/\/doi.org\/10.1056\/nejm199802123380706","journal-title":"N Engl J Med"},{"key":"4279_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/cmi.2017.134","volume":"15","author":"K Chen","year":"2018","unstructured":"Chen K, Bao Z, Tang P, Gong W, Yoshimura T, Wang JM (2018) Chemokines in homeostasis and diseases. Cell Mol Immunol 15:324\u2013334. https:\/\/doi.org\/10.1038\/cmi.2017.134","journal-title":"Cell Mol Immunol"},{"key":"4279_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109781","volume":"116","author":"Y Lin","year":"2023","unstructured":"Lin Y, Chen H, Ai Q, Yang Y, Zhang Z, Chu S, Chen N (2023) Characteristics and pathogenesis of chemokines in the post-stroke stage. Int Immunopharmacol 116:109781. https:\/\/doi.org\/10.1016\/j.intimp.2023.109781","journal-title":"Int Immunopharmacol"},{"key":"4279_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.neuint.2017.06.008","volume":"112","author":"C Chen","year":"2018","unstructured":"Chen C, Chu S-F, Liu D-D, Zhang Z, Kong L-L, Zhou X, Chen N-H (2018) Chemokines play complex roles in cerebral ischemia. Neurochem Int 112:146\u2013158. https:\/\/doi.org\/10.1016\/j.neuint.2017.06.008","journal-title":"Neurochem Int"},{"key":"4279_CR5","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1161\/strokeaha.111.000528","volume":"44","author":"J-K Strecker","year":"2013","unstructured":"Strecker J-K, Minnerup J, Sch\u00fctte-N\u00fctgen K, Gess B, Sch\u00e4bitz W-R, Schilling M (2013) Monocyte chemoattractant protein-1\u2013deficiency results in altered blood\u2013brain barrier breakdown after experimental stroke. Stroke 44:2536\u20132544. https:\/\/doi.org\/10.1161\/strokeaha.111.000528","journal-title":"Stroke"},{"key":"4279_CR6","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/01.wcb.0000071885.63724.20","volume":"23","author":"Y Chen","year":"2003","unstructured":"Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, Berman NEJ, Vogel SN (2003) Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab 23:748\u2013755. https:\/\/doi.org\/10.1097\/01.wcb.0000071885.63724.20","journal-title":"J Cereb Blood Flow Metab"},{"key":"4279_CR7","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1161\/strokeaha.107.513150","volume":"39","author":"S Terao","year":"2008","unstructured":"Terao S, Yilmaz G, Stokes KY, Russell J, Ishikawa M, Kawase T, Granger DN (2008) Blood cell-derived RANTES mediates cerebral microvascular dysfunction, inflammation, and tissue injury after focal ischemia\u2013reperfusion. Stroke 39:2560\u20132570. https:\/\/doi.org\/10.1161\/strokeaha.107.513150","journal-title":"Stroke"},{"key":"4279_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.jcbfm.9600432","volume":"27","author":"Y-P Yan","year":"2006","unstructured":"Yan Y-P, Sailor KA, Lang BT, Park S-W, Vemuganti R, Dempsey RJ (2006) Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab 27:1213\u20131224. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600432","journal-title":"J Cereb Blood Flow Metab"},{"key":"4279_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.brainres.2013.04.022","volume":"1517","author":"H Tokami","year":"2013","unstructured":"Tokami H, Ago T, Sugimori H, Kuroda J, Awano H, Suzuki K, Kiyohara Y, Kamouchi M et al (2013) RANTES has a potential to play a neuroprotective role in an autocrine\/paracrine manner after ischemic stroke. Brain Res 1517:122\u2013132. https:\/\/doi.org\/10.1016\/j.brainres.2013.04.022","journal-title":"Brain Res"},{"key":"4279_CR10","first-page":"119","volume":"77","author":"T Matsumoto","year":"1997","unstructured":"Matsumoto T, Ikeda K, Mukaida N, Harada A, Matsumoto Y, Yamashita J, Matsushima K (1997) Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab Invest 77:119\u2013125","journal-title":"Lab Invest"},{"key":"4279_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.cell.2019.01.044","volume":"176","author":"MT Joy","year":"2019","unstructured":"Joy MT, Assayag EB, Shabashov-Stone D, Liraz-Zaltsman S, Mazzitelli J, Arenas M, Abduljawad N, Kliper E et al (2019) CCR5 is a therapeutic target for recovery after stroke and traumatic brain injury. Cell 176:1143-1157.e13. https:\/\/doi.org\/10.1016\/j.cell.2019.01.044","journal-title":"Cell"},{"key":"4279_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/strokeaha.114.007298","volume":"46","author":"S Lee","year":"2015","unstructured":"Lee S, Chu HX, Kim HA, Real NC, Sharif S, Fleming SB, Mercer AA, Wise LM et al (2015) Effect of a broad-specificity chemokine-binding protein on brain leukocyte infiltration and infarct development. Stroke 46:537\u2013544. https:\/\/doi.org\/10.1161\/strokeaha.114.007298","journal-title":"Stroke"},{"key":"4279_CR13","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1161\/strokeaha.120.032782","volume":"52","author":"J Shi","year":"2021","unstructured":"Shi J, Li W, Zhang F, Park JH, An H, Guo S, Duan Y, Wu D et al (2021) CCL2 (C-C Motif Chemokine Ligand 2) Biomarker responses in central versus peripheral compartments after focal cerebral ischemia. Stroke 52:3670\u20133679. https:\/\/doi.org\/10.1161\/strokeaha.120.032782","journal-title":"Stroke"},{"key":"4279_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00508-015-0878-4","volume":"128","author":"D Bonifa\u010di\u0107","year":"2016","unstructured":"Bonifa\u010di\u0107 D, Toplak A, Benjak I, Tokmad\u017ei\u0107 VS, Leki\u0107 A, Ku\u010di\u0107 N (2016) Monocytes and monocyte chemoattractant protein 1 (MCP-1) as early predictors of disease outcome in patients with cerebral ischemic stroke. Wien Klin Wochenschr 128:20\u201327. https:\/\/doi.org\/10.1007\/s00508-015-0878-4","journal-title":"Wien Klin Wochenschr"},{"key":"4279_CR15","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.3390\/cells12182217","volume":"12","author":"H Pawluk","year":"2023","unstructured":"Pawluk H, Ko\u0142odziejska R, Grze\u015bk G, Wo\u017aniak A, Kozakiewicz M, Kosinska A, Pawluk M, Grze\u015bk-Kaczy\u0144ska M et al (2023) The potential role of RANTES in post-stroke therapy. Cells 12:2217. https:\/\/doi.org\/10.3390\/cells12182217","journal-title":"Cells"},{"key":"4279_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105421","volume":"160","author":"HS Hazelwood","year":"2022","unstructured":"Hazelwood HS, Frank JA, Maglinger B, McLouth CJ, Trout AL, Turchan-Cholewo J, Stowe AM, Pahwa S et al (2022) Plasma protein alterations during human large vessel stroke: a controlled comparison study. Neurochem Int 160:105421. https:\/\/doi.org\/10.1016\/j.neuint.2022.105421","journal-title":"Neurochem Int"},{"key":"4279_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0022-510x(01)00590-1","volume":"192","author":"AJ Grau","year":"2001","unstructured":"Grau AJ, Reis A, Buggle F, Al-Khalaf A, Werle E, Valois N, Bertram M, Becher H et al (2001) Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 192:41\u201347. https:\/\/doi.org\/10.1016\/s0022-510x(01)00590-1","journal-title":"J Neurol Sci"},{"key":"4279_CR18","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1161\/01.str.30.10.2174","volume":"30","author":"N Kostulas","year":"1999","unstructured":"Kostulas N, Pelidou SH, Kivis\u00e4kk P, Kostulas V, Link H (1999) Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 30:2174\u20132179. https:\/\/doi.org\/10.1161\/01.str.30.10.2174","journal-title":"Stroke"},{"key":"4279_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2147\/ndt.s391578","volume":"19","author":"M Han","year":"2023","unstructured":"Han M, Ma B, She R, Xing Y, Li X (2023) Correlations between serum CXCL9\/12 and the severity of acute ischemic stroke, a retrospective observational study. Neuropsychiatr Dis Treat 19:283\u2013292. https:\/\/doi.org\/10.2147\/ndt.s391578","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4279_CR20","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s10072-015-2341-8","volume":"36","author":"X-X Duan","year":"2015","unstructured":"Duan X-X, Zhang G-P, Wang X-B, Yu H, Wu J-L, Liu K-Z, Wang L, Long X (2015) The diagnostic and prognostic value of serum CXCL12 levels in patients with ischemic stroke. Neurol Sci 36:2227\u20132234. https:\/\/doi.org\/10.1007\/s10072-015-2341-8","journal-title":"Neurol Sci"},{"key":"4279_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.atherosclerosis.2011.10.004","volume":"220","author":"T Ueland","year":"2012","unstructured":"Ueland T, Smedbakken LM, Hall\u00e9n J, Atar D, Januzzi JL, Halvorsen B, Jensen JK, Aukrust P (2012) Soluble CXCL16 and long-term outcome in acute ischemic stroke. Atherosclerosis 220:244\u2013249. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.10.004","journal-title":"Atherosclerosis"},{"key":"4279_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/joim.12738","volume":"283","author":"A Simats","year":"2018","unstructured":"Simats A, Garc\u00eda-Berrocoso T, Penalba A, Giralt D, Llovera G, Jiang Y, Ramiro L, Bustamante A et al (2018) CCL23: a new CC chemokine involved in human brain damage. J Intern Med 283:461\u2013475. https:\/\/doi.org\/10.1111\/joim.12738","journal-title":"J Intern Med"},{"key":"4279_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12975-017-0545-3","volume":"8","author":"M Roy-O\u2019Reilly","year":"2017","unstructured":"Roy-O\u2019Reilly M, Ritzel RM, Conway SE, Staff I, Fortunato G, McCullough LD (2017) CCL11 (Eotaxin-1) levels predict long-term functional outcomes in patients following ischemic stroke. Transl Stroke Res 8:578\u2013584. https:\/\/doi.org\/10.1007\/s12975-017-0545-3","journal-title":"Transl Stroke Res"},{"key":"4279_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12883-015-0351-z","volume":"15","author":"E Klimiec","year":"2015","unstructured":"Klimiec E, Dziedzic T, Kowalska K, Szyper A, Pera J, Potoczek P, Slowik A, Klimkowicz-Mrowiec A (2015) PRospective Observational POLIsh Study on post-stroke delirium (PROPOLIS): methodology of hospital-based cohort study on delirium prevalence, predictors and diagnostic tools. BMC Neurol 15:94. https:\/\/doi.org\/10.1186\/s12883-015-0351-z","journal-title":"BMC Neurol"},{"key":"4279_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2174\/1871530320666200131110744","volume":"20","author":"A Jorda","year":"2019","unstructured":"Jorda A, Campos-Campos J, Iradi A, Aldasoro M, Aldasoro C, Vila JM, Valles SL (2019) The role of chemokines in Alzheimer\u2019s disease. Endocr, Metab Immune Disord - Drug Targets 20:1383\u20131390. https:\/\/doi.org\/10.2174\/1871530320666200131110744","journal-title":"Endocr, Metab Immune Disord - Drug Targets"},{"key":"4279_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-023-01254-1","volume":"15","author":"F Zhou","year":"2023","unstructured":"Zhou F, Sun Y, Xie X, Zhao Y (2023) Blood and CSF chemokines in Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and meta-analysis. Alzheimer\u2019s Res Ther 15:107. https:\/\/doi.org\/10.1186\/s13195-023-01254-1","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"4279_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.annemergmed.2013.05.003","volume":"62","author":"JH Han","year":"2013","unstructured":"Han JH, Wilson A, Vasilevskis EE, Shintani A, Schnelle JF, Dittus RS, Graves AJ, Storrow AB et al (2013) Diagnosing delirium in older emergency department patients: validity and reliability of the delirium triage screen and the brief confusion assessment method. Ann Emerg Med 62:457\u2013465. https:\/\/doi.org\/10.1016\/j.annemergmed.2013.05.003","journal-title":"Ann Emerg Med"},{"key":"4279_CR28","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1001\/jama.286.21.2703","volume":"286","author":"EWE Ely","year":"2001","unstructured":"Ely EWE, Inouye SKS, Bernard GRG, Gordon SS, Francis JJ, May LL, Truman BB, Speroff TT et al (2001) Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA, J Am Med Assoc 286:2703\u20132710. https:\/\/doi.org\/10.1001\/jama.286.21.2703","journal-title":"JAMA, J Am Med Assoc"},{"key":"4279_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1359-6101(97)00015-4","volume":"8","author":"LF Neville","year":"1997","unstructured":"Neville LF, Mathiak G, Bagasra O (1997) The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8:207\u2013219. https:\/\/doi.org\/10.1016\/s1359-6101(97)00015-4","journal-title":"Cytokine Growth Factor Rev"},{"key":"4279_CR30","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/S0026-895X(24)23229-6","volume":"57","author":"X Wang","year":"2000","unstructured":"Wang X, Li X, Schmidt DB, Foley JJ, Barone FC, Ames RS, Sarau HM (2000) Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke. Mol Pharmacol 57:1190\u20131198","journal-title":"Mol Pharmacol"},{"key":"4279_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11481-014-9560-2","volume":"9","author":"HA Seifert","year":"2014","unstructured":"Seifert HA, Collier LA, Chapman CB, Benkovic SA, Willing AE, Pennypacker KR (2014) Pro-inflammatory interferon gamma signaling is directly associated with stroke induced neurodegeneration. J Neuroimmune Pharmacol 9:679\u2013689. https:\/\/doi.org\/10.1007\/s11481-014-9560-2","journal-title":"J Neuroimmune Pharmacol"},{"key":"4279_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1742-2094-11-79","volume":"11","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Gao Z, Wang D, Zhang T, Sun B, Mu L, Wang J, Liu Y et al (2014) Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10. J Neuroinflammation 11:79. https:\/\/doi.org\/10.1186\/1742-2094-11-79","journal-title":"J Neuroinflammation"},{"key":"4279_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1750-3639.2010.00426.x","volume":"21","author":"GV Chaitanya","year":"2011","unstructured":"Chaitanya GV, Eeka P, Munker R, Alexander JS, Babu PP (2011) Role of cytotoxic protease granzyme-b in neuronal degeneration during human stroke. Brain Pathol 21:16\u201330. https:\/\/doi.org\/10.1111\/j.1750-3639.2010.00426.x","journal-title":"Brain Pathol"},{"key":"4279_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/acn3.595","volume":"5","author":"MJ Landreneau","year":"2018","unstructured":"Landreneau MJ, Mullen MT, Mess\u00e9 SR, Cucchiara B, Sheth KN, McCullough LD, Kasner SE, Sansing LH, Investigators the SMASCH (SMASCH) (2018) CCL2 and CXCL10 are associated with poor outcome after intracerebral hemorrhage. Ann Clin Transl Neurol 5:962\u2013970. https:\/\/doi.org\/10.1002\/acn3.595","journal-title":"Ann Clin Transl Neurol"},{"key":"4279_CR35","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/jcbfm.2015.45","volume":"35","author":"GC Jickling","year":"2015","unstructured":"Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR (2015) Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab 35:888\u2013901. https:\/\/doi.org\/10.1038\/jcbfm.2015.45","journal-title":"J Cereb Blood Flow Metab"},{"key":"4279_CR36","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1002\/jcp.27493","volume":"234","author":"H Lv","year":"2019","unstructured":"Lv H, Li J, Che Y (2019) CXCL8 gene silencing promotes neuroglial cells activation while inhibiting neuroinflammation through the PI3K\/Akt\/NF-\u03baB-signaling pathway in mice with ischemic stroke. J Cell Physiol 234:7341\u20137355. https:\/\/doi.org\/10.1002\/jcp.27493","journal-title":"J Cell Physiol"},{"key":"4279_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2119\/2007-00008.villa","volume":"13","author":"P Villa","year":"2007","unstructured":"Villa P, Triulzi S, Cavalieri B, Bitondo RD, Bertini R, Barbera S, Bigini P, Mennini T et al (2007) The interleukin-8 (IL-8\/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med 13:125\u2013133. https:\/\/doi.org\/10.2119\/2007-00008.villa","journal-title":"Mol Med"},{"key":"4279_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molimm.2018.08.002","volume":"101","author":"Q He","year":"2018","unstructured":"He Q, Shi X, Zhou B, Teng J, Zhang C, Liu S, Lian J, Luo B et al (2018) Interleukin 8 (CXCL8)-CXC chemokine receptor 2 (CXCR2) axis contributes to MiR-4437-associated recruitment of granulocytes and natural killer cells in ischemic stroke. Mol Immunol 101:440\u2013449. https:\/\/doi.org\/10.1016\/j.molimm.2018.08.002","journal-title":"Mol Immunol"},{"key":"4279_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41572-020-00223-4","volume":"6","author":"JE Wilson","year":"2020","unstructured":"Wilson JE, Mart MF, Cunningham C, Shehabi Y, Girard TD, MacLullich AMJ, Slooter AJC, Ely EW (2020) Delirium Nat Rev Dis Primers 6:90. https:\/\/doi.org\/10.1038\/s41572-020-00223-4","journal-title":"Delirium Nat Rev Dis Primers"},{"key":"4279_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jpsychores.2006.11.013","volume":"62","author":"SE de Rooij","year":"2007","unstructured":"de Rooij SE, van Munster BC, Korevaar JC, Levi M (2007) Cytokines and acute phase response in delirium. J Psychosom Res 62:521\u2013525. https:\/\/doi.org\/10.1016\/j.jpsychores.2006.11.013","journal-title":"J Psychosom Res"},{"key":"4279_CR41","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1186\/cc10598","volume":"15","author":"M van den Boogaard","year":"2011","unstructured":"van den Boogaard M, Kox M, Quinn KL, van Achterberg T, van der Hoeven JG, Schoonhoven L, Pickkers P (2011) Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients. Crit Care 15:R297\u2013R297. https:\/\/doi.org\/10.1186\/cc10598","journal-title":"Crit Care"},{"key":"4279_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/cce.0000000000000729","volume":"4","author":"RJ Smith","year":"2022","unstructured":"Smith RJ, Rabinstein AA, Cartin-Ceba R, Singh VP, Lachner C, Khatua B, Trivedi S, Gajic O (2022) Chemokines in ICU delirium: an exploratory study. Crit Care Explor 4:e0729. https:\/\/doi.org\/10.1097\/cce.0000000000000729","journal-title":"Crit Care Explor"},{"key":"4279_CR43","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/jcm10081587","volume":"10","author":"J Ka\u017amierski","year":"2021","unstructured":"Ka\u017amierski J, Miler P, Pawlak A, Jerczy\u0144ska H, Wo\u017aniak J, Frankowska E, Brzezi\u0144ska A, Wo\u017aniak K et al (2021) Elevated monocyte chemoattractant protein-1 as the independent risk factor of delirium after cardiac surgery. a prospective cohort study. J Clin Med 10:1587. https:\/\/doi.org\/10.3390\/jcm10081587","journal-title":"J Clin Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04279-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-024-04279-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-024-04279-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:06:12Z","timestamp":1736373972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-024-04279-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4279"],"URL":"https:\/\/doi.org\/10.1007\/s12035-024-04279-1","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by The Bioethics Committee of Jagiellonian University (KBET\/63\/B\/2014).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Each patient or his\/her legal guardian gave informed consent to participate in the study before data collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}